Institute Of Biomedical Stock Price To Earning
MRES Stock | USD 0.01 0.0005 5.38% |
Fundamental analysis of Institute allows traders to better anticipate movements in Institute's stock price by examining its financial health and performance throughout various phases of its business cycle.
Institute |
Institute of Biomedical Company Price To Earning Analysis
Institute's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition |
Based on the latest financial disclosure, Institute of Biomedical has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Institute Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Institute's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Institute could also be used in its relative valuation, which is a method of valuing Institute by comparing valuation metrics of similar companies.Institute is currently under evaluation in price to earning category among its peers.
Institute Fundamentals
Current Valuation | 198.84 K | |||
Shares Outstanding | 66.28 M | |||
Price To Book | 0.69 X | |||
Revenue | 1.41 M | |||
Net Income | 564.67 K | |||
Cash Flow From Operations | 2.06 M | |||
Beta | 1.71 | |||
Market Capitalization | 639.61 K | |||
Total Asset | 5.28 M | |||
Retained Earnings | (55.58 M) | |||
Current Asset | 2.56 M | |||
Current Liabilities | 3.8 M | |||
Z Score | -14.0 | |||
Net Asset | 5.28 M |
About Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Institute of Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Institute of Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Institute Pink Sheet Analysis
When running Institute's price analysis, check to measure Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Institute is operating at the current time. Most of Institute's value examination focuses on studying past and present price action to predict the probability of Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Institute's price. Additionally, you may evaluate how the addition of Institute to your portfolios can decrease your overall portfolio volatility.